TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07187531: SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

Sponsor: SAb Biotherapeutics, Inc. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 159 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,656,500

Rescue Site Savings

+$1,759,500

Unlock Full NCT07187531 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07187531 Rescue Dossier →